Yukozol Capsule 150 mg (Fluconazole)

Adult dose

The route of administration is determined according to the patient's clinical condition. Since absorption of the oral formulation is rapid and nearly complete, the doses of the oral formulations (tablets, capsules, dry syrup) and the injection formulation are the same. ○ Adults 1. Vaginal candidiasis: Administer a single oral dose of 150 mg of fluconazole. 2. Systemic candidiasis, including candidemia, disseminated candidiasis, and other invasive Candida infections (peritoneal, endocardial, pulmonary, urinary tract, etc.): Usually administer 400 mg of this drug once on the first day, followed by 200 mg once daily from the next day. The dose may be increased to 400 mg once daily according to the patient's response. The duration of treatment is determined according to clinical response and medical judgment. 3. Cryptococcal meningitis and cryptococcosis at other sites: Usually administer 400 mg of this drug once on the first day, followed by 200-400 mg once daily from the next day. The duration of treatment is determined by clinical and mycological response, but treatment should usually continue for at least 6 ~ 8 weeks. 4. To prevent recurrence of cryptococcal meningitis in patients with AIDS, administer 200 mg of this drug once daily indefinitely after the patient has completed all initial treatment. 5. Prevention of fungal infections in immunocompromised patients at risk due to neutropenia caused by cytotoxic chemotherapy, radiation therapy, or bone marrow transplantation: Administer 50-400 mg of this drug once daily according to the patient's risk of fungal infection. A dose of 400 mg once daily is recommended for patients at very high risk of systemic fungal infection, such as those with severe neutropenia or an expected prolonged period of neutropenia, as in the case of bone marrow transplantation. In such patients, administer 400 mg starting 5-6 days before the anticipated onset of neutropenia and continue 400 mg for 1 week after the neutrophil count has increased to 1,000 cells/mm3 or more. 6. For onychomycosis, administer 150 mg once weekly until the fingernails or toenails regrow (until new, uninfected nails grow). New fingernails usually take 3-6 months to grow, and toenails take approximately 6-12 months; growth rate may vary by individual and age. In some cases, nails may remain damaged after successful treatment with long-term administration. Dermal fungal infections, including tinea pedis, tinea corporis, tinea cruris, and cutaneous candidiasis: Usually administer 50 mg of this drug once daily or 150 mg once weekly for 2-4 weeks. However, tinea pedis may require treatment for 6 weeks depending on the course of the disease. For tinea versicolor, administer 50 mg once daily for 2-4 weeks. ○ Older adults If renal function is normal, administer the usual adult dose. In patients with renal impairment (creatinine clearance 50 mL/min or less), reduce the dose or extend the dosing interval. ○ Patients with renal impairment This drug is excreted primarily unchanged in the urine. Dose adjustment is not necessary when administering a single dose; however, when multiple doses are required, administer the usual dose only on the first day of treatment and adjust the dose from the next day as follows. Creatinine clearance (mL/min) / Recommended dose > 50: 100 % of the usual dose ≤50 (not on dialysis): 50% of the usual dose Patients on hemodialysis: 100% of the usual dose after each hemodialysis session Patients undergoing hemodialysis should receive 100% of the usual dose after each hemodialysis session. On days without dialysis, administer a reduced dose according to creatinine clearance.

This medication should not be used in certain patients. For example, it should not be taken by individuals allergic to this drug or similar ingredients, pregnant women, nursing mothers, or patients on certain other medications. Moreover, special caution is required for patients with kidney or liver problems or heart diseases while using this drug. This medication may affect heart rhythm, and patients at risk for arrhythmias should be particularly careful. This drug can interact with various medications, so it's essential to inform healthcare professionals if you are taking other drugs. Caution is especially needed when combined with heart-related medications, anticoagulants, antibiotics, antidepressants, etc. It is important to regularly monitor liver function, kidney function, and blood tests while taking this medication. Possible adverse reactions include headache, indigestion, skin rash, and liver function abnormalities, so if symptoms worsen, consult healthcare professionals immediately. Women who may become pregnant should use effective contraception before, during, and after taking this drug, and it is safest not to use this drug during pregnancy. In children, the safety of this drug in infants under 6 months has not been established, so it should only be used in special cases and after consulting an expert. Finally, caution is advised when driving or operating machinery, as dizziness or seizures may occur after taking this medication. Lastly, overdose of this drug may cause hallucinations or unusual behavior, so strict adherence to the prescribed dosage is essential, and in cases of overdose, seek appropriate treatment immediately.

Agranulocytosis, leukopenia, neutropenia, thrombocytopenia, anaphylaxis, angioedema, hypertriglyceridemia, hypercholesterolemia, hypokalemia, insomnia, drowsiness, headache, seizures, dizziness, paresthesia, dysgeusia, tremor, vertigo, Torsade de pointes, QT prolongation, abdominal pain, diarrhea, nausea, vomiting, dyspepsia, bloating, dry mouth, increased ALT, increased AST, increased serum alkaline phosphatase, cholestasis, jaundice, increased bilirubin, hepatotoxicity, liver failure, hepatocyte necrosis, hepatitis, hepatocellular injury, rash, itching, urticaria, increased sweating, drug rash, toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, exfoliative dermatitis, facial edema, hair loss, drug reaction with eosinophilia and systemic symptoms, myalgia, fatigue, lethargy, weakness, fever, adrenal insufficiency, hallucinations, psychotic behavior

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is best to keep the storage temperature between 1 and 30 degrees Celsius.

Appearance

A capsule filled with white powder, dark blue upper part, and light blue lower part.

Package unit

30 capsules per bottle